IFN-Á Responses in Peptide-treated Melanoma Patients Measured by an ELISPOT Assay Using Allogeneic Dendritic Cells

S Gabrielsson, V Brichard, O Dhellin, T Dorval… - Anticancer …, 2004 - ar.iiarjournals.org
Background: Several melanoma-specific peptides are currently used in clinical trials.
However, the monitoring of the T cell response remains non-standardised and is often …

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA

D Liénard, D Rimoldi, M Marchand, PY Dietrich… - Cancer immunity, 2004 - AACR
The purpose of this study was to test melanoma vaccines consisting of peptides and
immunological adjuvants for optimal immunogenicity and to evaluate laboratory immune …

[HTML][HTML] Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells

Y Akiyama, R Tanosaki, N Inoue, M Shimada… - Journal of Translational …, 2005 - Springer
Background Metastatic, chemotherapy-resistant melanoma is an intractable cancer with a
very poor prognosis. As to immunotherapy targeting metastatic melanoma, HLA-A2+ …

Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes

HM Hu, A Dols, SL Meijer, K Floyd… - Journal of …, 2004 - journals.lww.com
To facilitate the immunologic monitoring of a peptide vaccine trial, a novel, empty dimeric
HLA-A2 molecule (A2 dimer) that could be loaded with peptides was produced. The dimer …

Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay

C Scheibenbogen, KH Lee… - … journal of cancer, 1997 - Wiley Online Library
We have established a sensitive ELISPOT assay measuring interferon γ (IFN γ) release on a
single‐cell basis to detect influenza peptide‐specific CD8+ T cells in uncultured peripheral …

[HTML][HTML] Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial

AN Cornforth, G Lee, RO Dillman - BioMed Research International, 2011 - hindawi.com
Metastatic melanoma patients who were treated with patient-specific vaccines consisting of
dendritic cells loaded with autologous tumor cells had a 5-year survival of over 50 …

[PDF][PDF] Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell …

AC Peterson, H Harlin, TF Gajewski - Journal of clinical oncology, 2003 - psmrf.org
Purpose: Preclinical studies showed that immunization with peripheral blood mononuclear
cells (PBMC) loaded with tumor antigen peptides plus interleukin-12 (IL-12) induced CD8 T …

Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

GP Linette, D Zhang, FS Hodi, EP Jonasch… - Clinical cancer …, 2005 - AACR
Purpose: To determine the toxicity, maximal tolerated dose, and clinical and immunologic
response to autologous dendritic cells pulsed with melanoma-associated antigen gp100 …

Detection and quantification of CD8+ T cells specific for HLA‐A*0201‐binding melanoma and viral peptides by the IFN‐γ‐elispot assay

M Griffioen, M Borghi, PI Schrier… - International journal of …, 2001 - Wiley Online Library
Blood lymphocytes from HLA‐A* 0201‐subtyped melanoma patients and healthy controls
were screened for the presence of T cells specific for HLA‐A* 0201‐binding melanoma and …

Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination

US Kammula, FM Marincola… - Journal of the National …, 2000 - academic.oup.com
Background: Monitoring the immune response to epitope-specific vaccination in cancer
patients is important for vaccine development. The traditional method, in which the in vitro …